This article is more than 5 years old. Information may no longer be current.

Alimera reports consolidated net revenue increase in 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alimera Sciences reported $10.7 million in consolidated net revenue in the fourth quarter of 2016 and $34.3 million for the full year compared with $5.8 million and $22.4 million in 2015’s fourth quarter and full year, respectively.

The increases were attributed to an increase in demand for Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) to treat diabetic macular edema, according to an Alimera press release.

In the United States, net revenue increased about 70% to $25.8 million in 2016 compared with $15.2 million in 2015. International revenue increased by 18% to $8.6 million, attributed mostly to higher sales in Portugal and Germany.

The company’s net GAAP loss for the fourth quarter was approximately $5.9 million, or $0.09 per share, compared with a net loss of $10.7 million, or $0.24 per share, in 2015’s fourth quarter. For the year, the company reported a net loss of $33.2 million, or $0.63 per share, compared with a net loss of $30.6 million, or $0.69 per share, in 2015.